(SCIENCE EXPLAINED)
Weight Loss Scandals to Modern Day Weight Loss Magic
Weight-loss medications have evolved from dangerous stimulants of the 1940s to today's precision hormone therapies. The focus has shifted from simply suppressing appetite to treating obesity as a chronic metabolic disease driven by complex hormonal pathways.
Discovery of incretin hormones
The modern breakthrough began with the discovery of “Incretins” – gut hormones released after meals that regulate blood sugar, appetite, and energy balance. Two key incretins are GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide).
Scientists first focused on GLP-1 because it stimulates insulin release, suppresses glucagon, slows stomach emptying, and signals fullness to the brain. This led to the development of GLP-1 receptor agonists, culminating in drugs such as semaglutide (Ozempic/Wegovy). Introduced globally in 2018, these once-weekly injections improved blood-sugar control while producing significant weight loss by reducing hunger and increasing satiety.
The story behind GIP is fascinating. Back in the 1960s–70s, researchers noticed something strange: if a person drank glucose, the pancreas secreted much more insulin than when the same amount of glucose was given directly into the vein. This became known as the “incretin effect”. Scientists realized that the intestine must be releasing some hormone after food is eaten, which then signals the pancreas to produce insulin.
Researchers eventually identified one of these gut hormones and named it: Glucose-Dependent Insulinotropic Polypeptide (GIP). Unfortunately, it appeared less promising because its effects seemed diminished in people with Type 2 diabetes.
How did GIP suddenly become popular
So researchers largely prioritized GLP-1. However, a surprising discovery emerged. GIP alone was not impressive while GLP-1 alone was very good. But GLP-1 + GIP seemed better than either alone. Meaning, GIP could enhance and complement GLP-1 activity when both pathways were activated together. This achieved unprecedented improvements in blood-sugar control and average weight-loss results exceeding 20%. That’s how Mounjaro / Zepbound was born.
The Triple Agonist Breakthrough
The next frontier is triple-agonist therapy. Drugs such as “Retatrutide” target GLP-1, GIP, and glucagon receptors simultaneously, with clinical trials reporting weight-loss results approaching 30%. When retatrutide activates the glucagon receptor especially in the liver, the body releases stored energy, increases fat burning, increases heat production, increases resting energy expenditure, and reduces liver fat accumulation.
In simple terms:
GLP-1 = eat less
GIP = handles nutrients more effectively
Glucagon = burn more of what you have already stored
These advances are transforming obesity care, but they also reinforce an important reality: obesity is a chronic disease. Long-term success requires ongoing treatment, medical monitoring, healthy nutrition, regular physical activity, and sustainable lifestyle changes alongside these powerful new therapies.
– Zareer Patell - Black Belt, Fitness/Personal Trainer, Wellness Columnist and Consultant on Call (since 1972)
#GLP1 #GIP #ObesityMedicine #MetabolicHealth #WeightLoss #DiabetesCare #LifestyleMedicine #HealthEducation
Comments